Albert David Limited (ALBERTDAVD) — unitholding pattern

· NSE Neutral
📢 Key Event
Board approves Amit Mahla as additional director and whole-time director & CEO until 2031
🔄 What Changed
Appointment of Amit Mahla as whole-time director & CEO for five years
🔮 What's Next
Subject to shareholder approval at the 87th AGM
💡 Investor Takeaway
This leadership appointment strengthens executive continuity and strategic direction for the company.

The board approved the appointment of Amit Mahla as an additional director effective June 19, 2026, and as a whole-time director and CEO for five years until June 18, 2031, subject to shareholder approval at the upcoming 87th AGM. The notice for the AGM was revised to include these matters. The appointment follows his prior role as CEO since May 12, 2026, and reflects a strategic leadership addition with extensive pharmaceutical industry experience.

📄 View Original Announcement (PDF)

About Albert David Limited (ALBERTDAVD)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹411.4 Cr

View full ALBERTDAVD stock details →

📡 Get AI alerts when ALBERTDAVD files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ALBERTDAVD — Free

📊 More ALBERTDAVD filings

See all ALBERTDAVD filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when ALBERTDAVD files new disclosures

Track ALBERTDAVD filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ALBERTDAVD — Free

Free account · 2 AI queries/day